Arrowstreet Capital’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $538M | Sell |
8,872,779
-8,317,781
| -48% | -$485M | 0.29% | 71 |
|
|
2025
Q4 | $927M | Buy |
17,190,560
+2,356,583
| +16% | +$113M | 0.54% | 33 |
|
|
2025
Q3 | $669M | Buy |
14,833,977
+3,522,696
| +31% | +$165M | 0.42% | 50 |
|
|
2025
Q2 | $524M | Buy |
11,311,281
+9,171,098
| +429% | +$450M | 0.37% | 53 |
|
|
2025
Q1 | $131M | Buy |
2,140,183
+1,981,726
| +1,251% | +$116M | 0.11% | 178 |
|
|
2024
Q4 | $8.96M | Sell |
158,457
-1,872,718
| -92% | -$105M | 0.01% | 855 |
|
|
2024
Q3 | $105M | Sell |
2,031,175
-888,326
| -30% | -$41.7M | 0.09% | 194 |
|
|
2024
Q2 | $121M | Sell |
2,919,501
-412,074
| -12% | -$18.4M | 0.11% | 162 |
|
|
2024
Q1 | $181M | Buy |
3,331,575
+2,840,308
| +578% | +$145M | 0.17% | 118 |
|
|
2023
Q4 | $25.2M | Buy |
491,267
+319,553
| +186% | +$16.8M | 0.03% | 378 |
|
|
2023
Q3 | $9.97M | Buy |
+171,714
| New | +$10.5M | 0.01% | 519 |
|
|
2023
Q2 | – | Sell |
-985,908
| Closed | -$68.3M | – | 1227 |
|
|
2023
Q1 | $68.3M | Buy |
985,908
+721,425
| +273% | +$50.9M | 0.09% | 214 |
|
|
2022
Q4 | $19M | Sell |
264,483
-9,912
| -4% | -$747K | 0.03% | 412 |
|
|
2022
Q3 | $19.5M | Buy |
+274,395
| New | +$19.9M | 0.03% | 378 |
|
|
2022
Q2 | – | Sell |
-2,181,468
| Closed | -$159M | – | 1239 |
|
|
2022
Q1 | $159M | Sell |
2,181,468
-3,985,365
| -65% | -$268M | 0.2% | 130 |
|
|
2021
Q4 | $385M | Buy |
6,166,833
+132,211
| +2% | +$7.76M | 0.47% | 46 |
|
|
2021
Q3 | $357M | Buy |
6,034,622
+4,769,885
| +377% | +$314M | 0.45% | 43 |
|
|
2021
Q2 | $84.5M | Buy |
+1,264,737
| New | +$82.5M | 0.1% | 211 |
|
|
2020
Q3 | – | Sell |
-1,092,148
| Closed | -$64.2M | – | 2332 |
|
|
2020
Q2 | $64.2M | Sell |
1,092,148
-1,113,891
| -50% | -$66.6M | 0.12% | 156 |
|
|
2020
Q1 | $123M | Buy |
+2,206,039
| New | +$135M | 0.35% | 49 |
|
|
2019
Q4 | – | Sell |
-2,804,704
| Closed | -$142M | – | 1743 |
|
|
2019
Q3 | $142M | Sell |
2,804,704
-6,614,511
| -70% | -$311M | 0.33% | 79 |
|
|
2019
Q2 | $427M | Sell |
9,419,215
-5,319,461
| -36% | -$248M | 0.95% | 21 |
|
|
2019
Q1 | $703M | Sell |
14,738,676
-26,183
| -0.2% | -$1.3M | 1.66% | 3 |
|
|
2018
Q4 | $767M | Buy |
14,764,859
+299,601
| +2% | +$16.1M | 2.01% | 3 |
|
|
2018
Q3 | $898M | Buy |
14,465,258
+532,413
| +4% | +$31.6M | 2.03% | 5 |
|
|
2018
Q2 | $771M | Buy |
13,932,845
+7,362,915
| +112% | +$398M | 1.89% | 6 |
|
|
2018
Q1 | $416M | Buy |
6,569,930
+75,710
| +1% | +$4.87M | 0.95% | 20 |
|
|
2017
Q4 | $398M | Buy |
6,494,220
+1,417,638
| +28% | +$88.7M | 0.96% | 19 |
|
|
2017
Q3 | $324M | Buy |
5,076,582
+1,745,033
| +52% | +$102M | 0.87% | 25 |
|
|
2017
Q2 | $186M | Buy |
3,331,549
+3,323,649
| +42,072% | +$181M | 0.56% | 47 |
|
|
2017
Q1 | $430K | Buy |
+7,900
| New | +$433K | ﹤0.01% | 1114 |
|
|
2016
Q4 | – | Sell |
-1,648,479
| Closed | -$88.9M | – | 1697 |
|
|
2016
Q3 | $88.9M | Buy |
1,648,479
+1,458,113
| +766% | +$93.7M | 0.29% | 77 |
|
|
2016
Q2 | $14M | Sell |
190,366
-150,534
| -44% | -$10.6M | 0.05% | 356 |
|
|
2016
Q1 | $21.8M | Buy |
+340,900
| New | +$21.5M | 0.09% | 226 |
|
|
2015
Q4 | – | Sell |
-1,103,856
| Closed | -$65.3M | – | 1409 |
|
|
2015
Q3 | $65.3M | Sell |
1,103,856
-493,444
| -31% | -$31.3M | 0.31% | 69 |
|
|
2015
Q2 | $106M | Buy |
1,597,300
+1,426,500
| +835% | +$94M | 0.6% | 41 |
|
|
2015
Q1 | $11M | Buy |
+170,800
| New | +$10.7M | 0.07% | 260 |
|
|
2014
Q4 | – | Sell |
-1,533,092
| Closed | -$78.5M | – | 1233 |
|
|
2014
Q3 | $78.5M | Sell |
1,533,092
-67,985
| -4% | -$3.4M | 0.42% | 58 |
|
|
2014
Q2 | $77.7M | Buy |
1,601,077
+1,300,108
| +432% | +$64.1M | 0.4% | 56 |
|
|
2014
Q1 | $15.6M | Buy |
+300,969
| New | +$16M | 0.09% | 215 |
|
Other funds holding BMY
VCM
VPM
Arrowstreet Capital's BMY Position: Q1 2026 in Review
Arrowstreet Capital reduced its Bristol-Myers Squibb (BMY) stake by 48% in Q1 2026, selling an estimated $485M and leaving 8,872,779 shares worth $538M. The position accounts for 0.29% of the portfolio, ranked #71.
Arrowstreet Capital first reported a position in BMY in Q1 2014 and has held it in 40 quarters since. The position peaked at $927M in Q4 2025. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Arrowstreet Capital held 8,872,779 shares of Bristol-Myers Squibb worth $538M as of Q1 2026.
- Arrowstreet Capital sold 8,317,781 Bristol-Myers Squibb shares in Q1 2026, an estimated $485M.
- Bristol-Myers Squibb made up 0.29% of Arrowstreet Capital's portfolio in Q1 2026, its #71 holding.
- Arrowstreet Capital first reported a position in Bristol-Myers Squibb in Q1 2014 and has held it in 40 quarters since.
- Arrowstreet Capital's Bristol-Myers Squibb position peaked at $927M in Q4 2025.
- 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.